These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20491634)

  • 21. Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).
    Bell AS; Palmer MJ
    Expert Opin Ther Pat; 2011 Oct; 21(10):1631-41. PubMed ID: 21905762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
    Kayık G; Tüzün NŞ; Durdagi S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
    Samidurai A; Xi L; Das A; Kukreja RC
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug repurposing and the prior art patents of competitors.
    Sternitzke C
    Drug Discov Today; 2014 Dec; 19(12):1841-7. PubMed ID: 25269415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
    Bella AJ; Deyoung LX; Al-Numi M; Brock GB
    Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Determination, Biological Function, and Molecular Modelling Studies of Sulfoaildenafil Adulterated in Herbal Dietary Supplement.
    Kodchakorn K; Viriyakhasem N; Wongwichai T; Kongtawelert P
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33670094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tadalafil for the treatment of benign prostatic hyperplasia.
    Mónica FZ; De Nucci G
    Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
    Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2017 Dec; (6):160-163. PubMed ID: 29376615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction.
    Hudwekar AD; Kotwal P; Dar MI; Balgotra S; Dogra A; Kour J; Chobe SS; Nandi U; Hussain Syed S; Sawant SD
    Chem Biodivers; 2023 Apr; 20(4):e202200707. PubMed ID: 36915218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PDE5 inhibitors in the treatment of pulmonary hypertension].
    Dumitrescu D; Erdmann E; Rosenkranz S
    Pharm Unserer Zeit; 2010 Sep; 39(5):391-6. PubMed ID: 20818689
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.
    Roy S; Kloner RA; Salloum FN; Jovin IS
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):793-806. PubMed ID: 34652581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
    Peak TC; Richman A; Gur S; Yafi FA; Hellstrom WJ
    Sex Med Rev; 2016 Jan; 4(1):74-84. PubMed ID: 27872007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).
    Ribaudo G; Pagano MA; Bova S; Zagotto G
    Curr Med Chem; 2016; 23(12):1239-49. PubMed ID: 27121186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avanafil for the treatment of erectile dysfunction.
    Segal R; Burnett AL
    Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
    Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
    Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.